News

Artificial intelligence is poised to take over healthcare-or is it?

As communities grapple with the vaccine-preventable disease, healthcare orgs must step up to increase awareness.

Why status quo inpatient analytics fall short in unlocking clinical variability reduction.

The new drug is an add-on to levodopa/carbidopa for Parkinson’s patients experiencing “off” episodes.

Does step therapy harm patient outcomes?

How the new rule is affecting healthcare orgs.

Use of these meds to treat chronic hepatitis C in patients with moderate to severe liver impairment has resulted in liver failure in rare cases.

How a program with a goal of 1 million participants could help promote research into precision medicine.

Why it’s critical for healthcare orgs to optimize their supply chain networks.

Why price transparency is a top consumer demand.

Teva’s generic EpiPen Jr. helps alleviate allergy drug shortage.

Partnering with the right rewards provider can encourage plan members to take proactive steps toward improving their health.

DEA scrambles to add qualified marijuana growers.

From new models to AI, the things that get health execs excited about the future of healthcare.

Coverage is one step in the right direction, but there’s another part that is crucial.

New remote patient technology applications could be the new norm for healthcare.

How technology can improve patient and provider experiences.

How pen and paper can create risks for patient, providers, and visitors.

A new study has revealing findings about how millennials maintain their health and wellness.

A look at how consumerization is changing healthcare forever.

Increased transparency and consumer-friendliness are common goals in improving billing, but more work is needed.

How nonprofit hospitals and health systems are getting involved with housing.

Telehealth being used to fill patient care gaps.

A new survey shows that despite concerns, most people view their experiences with healthcare positively.

Two organizations partner to help fund community-based organizations.

Millennials and Baby Boomers aren't so different after all. 

FDA approved the third oncology drug in the US that targets a key genetic driver of cancer, rather than a specific tumor.

Blockbuster drug could be key to Humira’s successor.